City of Hope National Medical Center
City of Hope National Medical Center
Duarte, California, United States68 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-10-09 | NCT07476287 | |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT05789082 | |
| Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04623541 | |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06982521 | |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03478514 | |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal adenocarcinoma, esophageal cancer, esophageal disorder, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, head and neck cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, squamous cell neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Recruiting | Phase 1 | 2026-10-01 | NCT07090499 | |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-09-30 | NCT05611931 | |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-09-30 | NCT05382559 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 3 | 2026-09-25 | NCT06561048 | |
| A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-09-25 | NCT04108195 | |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07213674 | |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2026-09-21 | NCT05296070 | |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT04752826 | |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-15 | NCT06492616 | |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-09-14 | NCT06846606 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04246086 | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | large B-cell lymphoma | Active, not recruiting | Phase 3 | 2026-09-11 | NCT06047080 | |
| A Study of KK2269 in Adult Participants With Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-10 | NCT06266299 | |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT06966453 | |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT04588922 | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 2 | 2026-08-28 | NCT00781612 | |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium adenocarcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-08-21 | NCT05548296 | |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) | Cytopenia, Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-08-21 | NCT04419649 | |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Bites and Stings, Chemically-Induced Disorders, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, injury, male reproductive organ cancer, male reproductive system disorder, neoplasm, poisoning, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-08-21 | NCT04221542 | |
| Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-08-19 | NCT07499674 |